CompanyDrug

Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment

CompanyMedical Device

Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study

CompanyDrug

Grand Pharmaceutical’s APP13007 Achieves Clinical Endpoints in US Trials for Post-Operative Treatment

CompanyDrug

Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G

CompanyDrug

Shanghai Fosun Pharmaceutical Submits Market Approval Filing for Daxibotulinumtoxin A in China

CompanyDrug

Junshi Biosciences’ Senaparib Meets Primary Endpoint in Phase III Ovarian Cancer Study

Company

Porton Pharma Solutions Expands with Biomacromolecules R&D and Manufacturing Center in Shanghai

CompanyDeals

Blueray Med Secures Tens of Millions in Series A+ Financing for Advanced Laser Medicine Devices

CompanyDeals

Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC

Company

Legend Biotech Appoints Dr. Mythili Koneru as Chief Medical Officer to Lead Clinical Development

CompanyDrug

Luye Pharma’s Bevacizumab Biosimilar Accepted for Review in Brazil by ANVISA

Policy / Regulatory

Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers